Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

Effects of resistance and aerobic exercise on physical function, bone mineral density, OPG and RANKL in older women.

Marques EA, Wanderley F, Machado L, Sousa F, Viana JL, Moreira-Gonçalves D, Moreira P, Mota J, Carvalho J.

Exp Gerontol. 2011 Jul;46(7):524-32. doi: 10.1016/j.exger.2011.02.005. Epub 2011 Feb 23.

PMID:
21316442
2.

Response of bone mineral density, inflammatory cytokines, and biochemical bone markers to a 32-week combined loading exercise programme in older men and women.

Marques EA, Mota J, Viana JL, Tuna D, Figueiredo P, Guimarães JT, Carvalho J.

Arch Gerontol Geriatr. 2013 Sep-Oct;57(2):226-33. doi: 10.1016/j.archger.2013.03.014. Epub 2013 Apr 23.

PMID:
23623588
3.

Multicomponent training program with weight-bearing exercises elicits favorable bone density, muscle strength, and balance adaptations in older women.

Marques EA, Mota J, Machado L, Sousa F, Coelho M, Moreira P, Carvalho J.

Calcif Tissue Int. 2011 Feb;88(2):117-29. doi: 10.1007/s00223-010-9437-1. Epub 2010 Nov 27.

PMID:
21113584
4.
5.

Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.

Nabipour I, Larijani B, Vahdat K, Assadi M, Jafari SM, Ahmadi E, Movahed A, Moradhaseli F, Sanjdideh Z, Obeidi N, Amiri Z.

Menopause. 2009 Sep-Oct;16(5):950-5. doi: 10.1097/gme.0b013e3181a181b8.

PMID:
19387415
7.

Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis.

Reyes-García R, Muñoz-Torres M, García DF, Mezquita-Raya P, García Salcedo JA, de Dios Luna J.

Menopause. 2010 Jan-Feb;17(1):140-4. doi: 10.1097/gme.0b013e3181ac0cc1.

PMID:
19574937
9.

The effect of RANKL and OPG on bone mineral density in pre-dialysis chronic renal failure.

Fahrleitner-Pammer A, Dobnig H, Dimai HP, Holzer H, Benesch T, Borchhardt K, Cejka D, Haas M.

Clin Nephrol. 2009 Jun;71(6):652-9.

PMID:
19473634
10.

Osteoprotegerin and RANKL in the pathogenesis of osteoporosis in patients with thalassaemia major.

Pietrapertosa AC, Minenna G, Colella SM, Santeramo TM, Renni R, D'Amore M.

Panminerva Med. 2009 Mar;51(1):17-23.

11.

Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins.

Abrahamsen B, Hjelmborg JV, Kostenuik P, Stilgren LS, Kyvik K, Adamu S, Brixen K, Langdahl BL.

Bone. 2005 Apr;36(4):727-35.

PMID:
15781001
12.

RANKL:osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositis.

Rouster-Stevens KA, Langman CB, Price HE, Seshadri R, Shore RM, Abbott K, Pachman LM.

Arthritis Rheum. 2007 Mar;56(3):977-83.

13.

Effects of resistance training on regional and total bone mineral density in premenopausal women: a randomized prospective study.

Lohman T, Going S, Pamenter R, Hall M, Boyden T, Houtkooper L, Ritenbaugh C, Bare L, Hill A, Aickin M.

J Bone Miner Res. 1995 Jul;10(7):1015-24.

PMID:
7484276
14.

Maintained malnutrition produces a progressive decrease in (OPG)/RANKL ratio and leptin levels in patients with anorexia nervosa.

Muñoz-Calvo MT, Barrios V, García de Alvaro MT, Lefort M, Méndez-Dávila C, Argente J, de la Piedra C.

Scand J Clin Lab Invest. 2007;67(4):387-93.

PMID:
17558893
15.

Calcium and Magnesium Supplementation Improves Serum OPG/RANKL in Calcium-Deficient Ovariectomized Rats.

Bae YJ, Kim MH.

Calcif Tissue Int. 2010 Oct;87(4):365-72. doi: 10.1007/s00223-010-9410-z. Epub 2010 Sep 2.

PMID:
20811796
16.

Serum osteoprotegerin and its ligand in cirrhotic patients referred for orthotopic liver transplantation: relationship with metabolic bone disease.

Monegal A, Navasa M, Peris P, Alvarez L, Pons F, Rodés J, Guañabens N.

Liver Int. 2007 May;27(4):492-7.

PMID:
17403189
17.

Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone.

Martini G, Gennari L, Merlotti D, Salvadori S, Franci MB, Campagna S, Avanzati A, De Paola V, Valleggi F, Nuti R.

Bone. 2007 Feb;40(2):457-63. Epub 2006 Sep 18.

PMID:
16979395
18.

Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene.

Bashir A, Mak YT, Sankaralingam S, Cheung J, McGowan NW, Grigoriadis AE, Fogelman I, Hampson G.

Steroids. 2005 Dec 1;70(13):847-55. Epub 2005 Jul 7.

PMID:
16005483
19.

The effect of zoledronic acid on serum dickkopf-1, osteoprotegerin, and RANKL in patients with Paget's disease of bone.

Polyzos SA, Anastasilakis AD, Efstathiadou Z, Kita M, Litsas I, Avramidis A, Arsos G, Moralidis E, Gerou S, Pavlidou V, Papatheodorou A, Terpos E.

Horm Metab Res. 2009 Nov;41(11):846-50. doi: 10.1055/s-0029-1233491. Epub 2009 Aug 10.

PMID:
19670154
20.

Increased RANKL/OPG mRNA ratio in iliac bone biopsies from women with hip fractures.

Abdallah BM, Stilgren LS, Nissen N, Kassem M, Jørgensen HR, Abrahamsen B.

Calcif Tissue Int. 2005 Feb;76(2):90-7. Epub 2004 Nov 18.

PMID:
15570403

Supplemental Content

Support Center